The Cost-Effectiveness of Ustekinumab in Moderate to Severely Active Crohn’s Disease in Sweden

Autor:	L Karlsson, C Almond, A Hansson-Hedblom, Dana Enkusson, I Sly, Fredrik Borgström, A Troelsgaard Buchholt
Rok vydání:	2017
Předmět:	Crohn's disease Pediatrics medicine.medical_specialty Cost effectiveness business.industry Health Policy Ustekinumab Public Health Environmental and Occupational Health medicine medicine.disease business medicine.drug
Zdroj:	Value in Health. 20:A634
ISSN:	1098-3015
DOI:	10.1016/j.jval.2017.08.1435
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::49f81d72941ab145372fcac68e801316 https://doi.org/10.1016/j.jval.2017.08.1435 Zobrazit plný text záznamu Full Text from ScienceDirect